A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia

Acta Pharmacologica Sinica

Volumn 30, Issue 10, 2009, Pages 1471-1478

  Li, Qiu Bai ^a   Li, Lei ^a   You, Yong ^a   Chen, Zhi Chao ^a   Xia, Ling Hui ^a   Zou, Ping ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Allogeneic stem cell transplantation; Etoposide; High risk acute leukemia; Idarubicin; Intensified conditioning regimen

Indexed keywords

ACICLOVIR; BASILIXIMAB; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; GANCICLOVIR; HYDROXYUREA; IDARUBICIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENOBARBITAL; PROSTAGLANDIN E1; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HIGH RISK PATIENT; HUMAN; LUNG ASPERGILLOSIS; LUNG HEMORRHAGE; MALE; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; MYELOABLATIVE CONDITIONING; NAUSEA; PNEUMOCYSTOSIS; PNEUMONIA; SEIZURE; TREATMENT OUTCOME; VEIN OCCLUSION; VOMITING; WHOLE BODY RADIATION;

ACUTE DISEASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPERGILLUS; BUSULFAN; CHINA; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYUREA; IDARUBICIN; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; LEUKEMIA, MYELOID, ACUTE; MALE; METHYLPREDNISOLONE; MUCOSITIS; PNEUMONIA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREMEDICATION; RETROSPECTIVE STUDIES; RISK FACTORS; SEMUSTINE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 70350678885     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.132     Document Type: Article

References (26)

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-1826
2. Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi R, et al. Comparison between two fludarabine-based reducedintensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia 2007; 2: 2109-2116
3. Thomas ED. Marrow transplantation for malignant disease (Karnofsky Memorial Lecture). J Clin Oncol 1983; 1: 517-531
4. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008; 112: 3574-3581
5. Laport GG, Alvarnas JC, Palmer JM, Snyder DS, Slovak ML, Cherry AM, et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood 2008; 112: 903-909
6. Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, et al. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Haematologica 2002; 87: 52-58
7. Anderson JE, Gooley TA, Schoch G, Anasetti C, Bensinger WI, Clift RA, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997; 89: 2578-2585
8. Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A, et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood 2008; 112: 415-425
9. Huang XJ. Advance in hematopoietic stem cells transplantation for leukemia. Chin Med J (Engl) 2008; 121: 1763-1765
10. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767-776
11. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050
12. Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007; 110: 2744-2748
13. Vaughan WP, Dennison JD, Reed EC, Klassen L, McGuire TR, Sanger WG, et al. Improved results of allogeneic bone marrow trans - planta tion for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy. Bone Marrow Transplant 1991; 8: 489-495
14. Hirabayashi N, Goto S, Ishii M, Yuge M, Mitsuma A, Noda N. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia. Bone Marrow Transplant 1998; 21: 1079-1083
15. Brown RA, Wolff SN, Fay JW, Pineiro L, Collins RH Jr, Lynch JP, et al. High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for resistant acute myeloid leukemia: a study by the North American Marrow Transplant Group. Leuk Lymphoma 1996; 22: 271-277
16. Blume KG, Kopecky KJ, Henslee-Downey JP, Forman SJ, Stiff PJ, LeMaistre CF, et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group Study. Blood 1993; 81: 2187-2193
17. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083
18. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLAmismatched/ haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065-3073
19. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568
20. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387-9393
21. You Y, Li QB, Chen ZC, Li WM, Xia LH, Zhou H, et al. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation. Chin Med J (Engl) 2008; 121: 1770-1774
22. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug resistant leukemia cells. Blood 1992; 79: 3267-3276
23. Mengarelli A, Iori AP, Guglielmi C, Perrone MP, Gozzer M, Girmenia C, et al. Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies. Leukemia 2000; 14: 2052-2058
24. Henwood JM, Brogden RN. Etoposide. A review of its pharmacodynamic and pharmacokinetic propertyes, and therapeutic potential in combination chemotherapy of cancer. Drugs 1990; 39: 438-490
25. Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, et al. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Bone Marrow Transplantation 2000; 26: 711-716
26. Grigg AP, Szer J, Beresford J, Dodds A, Bradstock K, Durrant S, et al. Factors affecting the outcome of allogeneic bone marrow trans plantation for adult patients with refractory or relapsed acute leukemia. Br J Haematol 1999; 107: 409-418